We retrospectively evaluated the efficacy of autologous hematopoietic stem cell transplantation (AHSCT) in 18 patients with rapidly progressive diffuse cutaneous systemic sclerosis (rp-dcSSc), and compared their disease outcomes with those of 36 demographically-and clinically-matched patients treated with conventional therapies. Cutaneous involvement, by performing modified Rodnan skin score (mRss), lung diffusion capacity, by measuring diffusing capacity of lung for carbon monoxide (DLCO), and disease activity, by applying the European Scleroderma Study Group (ESSG) scoring system, were the outcome variables measured at the baseline time and then every 12 months for the following 60 months in both the AHSCT-treated patients and the control group. In the AHSCT group, treatment-related mortality was 5.6%. In this group, both mRss and ESSG scores showed a significant reduction 1 year after AHSCT (P o 0.002); and these results were maintained until the end of follow-up. Conversely, DLCO values remained stable during the whole period of follow-up. Survival rate of AHSCT group was much higher than that observed in the whole control group (P = 0.0005). The probability that the ESSG score and mRss would remain at a high level, and DLCO could decrease, was significantly higher in the control group as a whole and in the subgroup of control patients treated with cyclophosphamide than in the AHSCT group. This study confirms that the AHSCT is effective in prolonging survival, as well as in inducing a rapid reduction of skin involvement and disease activity, and preserving lung function in patients with rp-dcSSc.
INTRODUCTION
Systemic sclerosis (SSc) is a rare multifaceted autoimmune disorder characterized by inflammatory, vascular and fibrotic processes resulting in skin fibrosis and multiple organ manifestations. 1 Although there has been significant progress over the years in identifying the early phases of the disease, and recognizing different clinical phenotypes with variable course, really effective therapy remains an unsolved issue. 2 The pathogenesis of SSc is still poorly understood, hence treatment of this condition is difficult and often 'organ-based'. Treatment options have targeted different pathogenic processes, including inflammation, immune dysregulation and fibrosis, showing only limited efficacy. To date, SSc is still characterized by high morbidity and increased mortality, mainly in the severe progressive variant of the disease. 3 Over the past 20 years, cyclophosphamide (CYC) has been considered as the standard of care for SSc, namely in patients with early aggressive skin disease and concomitant interstitial lung disease (ILD). 4 However, two randomized, placebo-controlled trials involving patients with SSc failed to demonstrate any real efficacy of CYC on lung function and disease progression. [5] [6] [7] Similarly, two meta-analyses of prospective studies using oral or IV CYC in SSc-related ILD did not report any improvement in lung function. 8, 9 With regard to other immunosuppressive agents such as azathioprine, methotrexate, rituximab and mycophenolate, there is limited evidence that these drugs may be effective in changing the natural history of scleroderma disease. Promising results have been reported in pilot studies concerning single organ involvement, but these preliminary data are still waiting to be confirmed in controlled and adequately powered studies. 10 Given the lack of effective disease-modifying treatments in SSc, it is not surprising that SSc was one of the first autoimmune diseases challenged with high-dose immunosuppressive treatment followed by autologous hematopoietic stem cell transplantation (AHSCT). Over the past 15 years, several reports have shown beneficial effects of AHSCT on clinical manifestations of SSc, namely on skin thickening. 11 Additional evidence supporting AHSCT comes from two randomized, placebo-controlled trials showing the superiority of AHSCT when compared with CYC pulse therapy. 12, 13 An additional American RCT (scleroderma: cyclophosphamide or transplantation (SCOT)) is currently underway. 14 The present study was aimed at retrospectively analyzing the long-term outcome observed in our cohort of patients with rapidly progressive diffuse cutaneous SSc (rp-dcSSc) who underwent AHSCT. This outcome was also compared with that observed in an age-and sex-matched group of clinically similar patients treated with conventional therapies. 
PATIENTS AND METHODS

Study protocol
In this study, we retrospectively analyzed the data obtained from 18 patients suffering from rp-dcSSc, who underwent AHSCT in our center from 2003 to 2011, and then were regularly followed up for up to 5 years. All the enrolled patients met the 1993 American College of Rheumatology (formerly, the American Rheumatism Association) criteria for SSc 15 and, when retrospectively evaluated, also the new ACR-EULAR criteria. 16 Our selection of candidates for AHSCT included any patient with rp-dcSSc whose response to conventional immune-suppressive therapies was nil or very unsatisfactory. Previous unsuccessful immunosuppressive treatment included methotrexate (15-25 mg/week) in 10 patients, azothioprine (100-200 mg/day) in 4, CYC (1 g monthly for 2 months) in 4, in all of the patients associated with low-dose prednisone (⩽7.5 mg/day).
Criteria for inclusion were a modified Rodnan skin score (mRss) of ⩾ 14, 17 a clinical activity score of at least 3, according to the European Scleroderma Study Group (ESSG) scoring system, 18 and a disease duration of o 4 years. This cutoff value for disease duration was chosen in agreement with that done in other studies, namely the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial. 13 As to disease activity level, all of the patients selected for AHSCT had an ESSG score of 4 or more.
Important co-morbidities and any pre-existing or current severe diseaserelated organ involvement, such as pulmonary arterial hypertension (detected by echocardiography and confirmed by right catheterism), scleroderma renal crisis, ILD (with a diffusing capacity of lung for carbon monoxide (DLCO) under 50% of the predicted value) and scleroderma cardiopathy (with an ejection fraction below 45%), were considered all exclusion criteria for AHSCT. To have a correct selection, a complete clinical and instrumental work up was made before starting the transplantation procedure.
None of the transplanted patients enrolled in this study was included in other studies and namely in the ASTIS trial, although some of the authors of the present study took part in that multicenter survey.
To better evaluate the potential clinical benefits induced by AHSCT, we compared the group of transplanted patients with a control group of patients with rp-dcSSc selected from our historical cohort. Data from most of these patients were collected between 1991 and 2003 before AHSCT was adopted as a potential therapeutic strategy. Some patients enrolled between 2004 and 2009 who could be considered as potential candidates for AHSCT were also included in the control group. They were directed to receive conventional therapeutic strategies because they did not consent to the AHSCT procedure.
The method of selection of patients included in the control group was the following. Flicking through our database of over 300 patients with SSc listed in alphabetic order, we selected the first two patients who had the same demographic and clinical characteristics as each patient who underwent AHSCT. Consequently, even control patients, on the basis of a clinical and instrumental work up performed immediately before starting the conventional treatment, did not have severe co-morbidities and severe disease-related organ involvement, like pulmonary arterial hypertension, previous or current scleroderma renal crisis, ILD with a DLCO under 50% of the predicted value and a cardiac involvement with an ejection fraction below 45%. The 36 selected control patients had been treated with different immunosuppressive regimens. On the basis of the immunosuppressive treatment that patients had received, the control group could be subdivided into two subgroups: (a) 25 patients treated with monthly pulse CYC (CYC group) (1000 mg each for 6 months, in some with additional pulses at 9th and 12th month), in association with low-dose prednisone (5-10 mg/day) and (b) 11 patients treated with other immunosuppressive regimens (No-CYC group), such as methotrexate (10-20 mg weekly) or azathioprine (100-200 mg/day), in association with low-dose prednisone (5-10 mg/day), or pulse methylprednisolone followed by low-dose azathioprine (in 2 patients).
A 5-year follow-up was taken into account even in the control group, starting from the baseline clinical assessment of each patient made immediately before starting the medical treatment. A complete clinical and instrumental work up was repeated every year also for the control patients.
Transplantation procedure
The AHSCT procedure was performed similarly to that done in previous studies. 13 Briefly, previous unsuccessful immunosuppressive therapies were discontinued at least 1 month before the mobilization procedure. First, PBSCs were mobilized by using IV CYC (a total of 4 g/m 2 administered in equal amounts in 2 days) and filgrastim (10 μg/kg per day, starting after 5 days of CYC administration), and harvested by leukapheresis. PBSCs enriched for CD34+ cells were isolated using an immunomagnetic separation method (CliniMACS, Miltenyi Biotec, Bologna, Italy). In the transplantation phase, the conditioning regimen consisted of IV CYC for a total dose of 200 mg/kg, subdivided into 4 equal doses from day − 5 to − 2 and rabbit antithymocyte globulin at a total dose of 7.5 mg/kg (subdivided into equal doses from day − 3 to − 1). Hyperhydration and treatment with mesna were associated with CYC to prevent hemorrhagic cystitis, whereas IV methylprednisolone 1 mg/kg was associated with antithymocyte globulin to improve its tolerability. On day 0, autologous CD34 + -selected stem cells (⩾2 × 10 6 /kg) were thawed and immediately infused. All patients received acyclovir, cyprofloxacine and fluconazole for infection prophylaxis.
Outcome measures
Overall survival in transplanted patients and in the control group was calculated from the baseline clinical assessment. Assessment of AHSCT-related mortality, defined as any death within 100 days after transplantation in the absence of relapse or progression of SSc, was also included among the objectives of this study.
For the purpose of the present study and to more precisely assess the disease response to treatment in both transplanted patients and controls, we selected specific outcome measures able to provide quantitative or semi-quantitative assessment of different disease features. In particular, we considered (a) the extent of skin involvement measured by the mRss; (b) the degree of lung function impairment assessed by DLCO (expressed as a percentage of the predicted value and adjusted for hemoglobin level) and (c) the overall assessment of disease activity, by using the ESSG scoring system. 18 
Statistical analysis
According to previous studies, and namely looking at ASSIST trial 12 that was based on the probability of 60% mortality at 5 years in patients treated with CYC, reduced to 25% in transplanted patients, we assumed that significant differences in survival rates and other outcome measures could be observed comparing our transplanted patients (18 patients) with a comparable number of control patients, with a two-sided test and 80% power. We decided to randomly select from our database 36 patients treated with different conventional treatments, to be sure that at least half of them had received a CYC treatment. Changes of the considered outcome measures recorded at different observation times (12 (T1), 24 (T2), 36 (T3), 48 (T4) and 60 (T5) months after the enrollment) were compared with the corresponding baseline values (T0) using the two-sided Wilcoxon paired test. The P-values obtained were adjusted for multiple comparisons using Bonferroni's method.
Kaplan-Meier estimates and log-rank test were used to compare overall survival observed in the different groups of patients by computing hazard ratio (HR) with 95% confidence interval (CI). The same statistical approach was adopted to analyze the cumulative probability of variation from baseline values of mRss, DLCO and ESSG activity score during the 5-year follow-up in the same groups.
Ethical rules
The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee. All the patients included in the study provided written informed consent to the conferred treatment.
RESULTS
Patients' characteristics at the time of enrollment The 18 transplanted patients (13 females and 5 males) had a median age of 41 years (ranging from 20 to 64), a median disease duration of 24 months (ranging from 10 to 47), and a median baseline mRss of 20 (ranging from 15 to 32). Twelve patients (67%) at the baseline assessment showed pulmonary involvement with evidence of mild ILD at HRCT, with a median DLCO equal to 68% of the predicted value (ranging from 51 to 100) ( Table 1) . As far as disease activity level in the AHSCT-treated group is concerned, all of the enrolled patients had an ESSG score of 4 or more. This figure was mostly due to the fact that these patients at the time of enrollment had shown signs or symptoms of new appearance or rapid worsening of skin, lung and heart involvement.
Twenty-six females and ten males with a median age 44 years (range 19-62 years) formed the control group of rp-dcSSc patients. At the baseline evaluation point, this control group was also strictly comparable to the AHSCT group for demographic characteristics and levels of disease activity, skin score and lung involvement (Table 1) .
Response to AHSCT procedure Following the AHSCT, one patient died from interstitial pneumonia at day 65, accounting for a transplant-related mortality of 5.6%. The data from this patient were not considered in analysis when we analyzed the disease-related outcome variables in the AHSCT-treated patients. The adverse events observed during the whole transplantation procedure were not different, in terms of prevalence and severity, from those reported in previous similar studies. In particular, in the mobilization phase we observed three cases of fever of unknown origin, one case of mucositis and one case of hemorrhagic cystitis. In the transplantation phase, we recorded eight cases of fever of unknown origin, five cases of fever with positive blood culture and three cases of pneumonia. All the observed infections resolved thanks to adequate antibiotic treatment. In one case, we observed a transient reduction of left ventricular ejection fraction, and in another one a phase of arterial hypotension due to unexplained polyuria that required adequate re-hydration. No significant modifications of the SSc disease course were observed immediately after the mobilization phase and transplantation procedure.
Concerning the therapeutic effect of transplantation procedure in our patients, both mRss and ESSG scores showed a strongly significant reduction already at T1 after AHSCT. Afterwards, the ESSG score was maintained around the same level during the whole follow-up period. As far as mRss is concerned, a further significant reduction was observed at T2 with respect to T1. No significant modification of DLCO values was recorded at any time after transplantation during the follow-up period (Figures 1a-c) . T0  T1  T2  T3  T4  T5   T0  T1  T2  T3  T4  T5   T0  T1  T2  T3  T4 When the transplanted patients were subdivided according to their baseline disease activity into those with an ESSG score of ⩾ 6 and those with an ESSG score ranging from 4 to 5, no significant differences were observed in the different outcome measures. The results of this comparison are reported in detail in Table 2 .
Comparison between AHSCT-treated and conventionally treated patients Among the 17 patients who survived after AHSCT, only one (5.8%) died during the follow-up due to an SSc-related manifestation (a fatal cardiac arrhythmia occurring after 34 months). In contrast, the disease-related mortality at the end of the entire follow-up period in the whole control group was 61% (P = 0.0005). In particular, in the CYC subgroup the cumulative disease-related mortality was 0% at T1, 12% at T2, 20% at T3, 32% at T4 and 56% at T5 (Figure 2) .
We also analyzed the ESSG score modifications in the group of AHSCT-treated patients compared to that observed in the whole control group, and in the CYC subgroup. The probability that this score may fall to under 3 is over 80% at T1 in the transplanted patients, while it is below 20% at T5 in both the whole control group and the CYC-treated subgroup (Figure 3a) .
When the mRss curve was analyzed, the probability that the initial score could fall to under 14 points was over 90% at T1 in the AHSCT group, while it was a little over 60% at 3 years in both the whole control group and the CYC-treated patients (Figure 3b) .
Likewise, the estimated probability that DLCO fell to under 50% of the predicted value at T5 was below 20% in the AHSCT group, and over 60% in both the whole control group and the CYC-treated subgroup at T5 (Figure 3c ).
When we compared the different outcome parameters in the control patients subdivided into those treated with immunosuppressive therapy between 1991 and 2003 (16 patients) and those who were enrolled after 2003 and treated also with immunosuppressive therapies because they refused to undergo AHSCT (20 patients), we did not observe any significant differences between the two subgroups. A slight trend to have better outcomes, however, was recorded in the more recent group. In particular, survival rate was 37.5% at T5 in the former group and 45.0% at T5 in the latter group.
DISCUSSION
The present study indicates that AHSCT in patients with rp-dcSSc is effective in reducing disease-related mortality, and in lowering both disease activity and severity of skin involvement, and in preserving lung diffusion capacity. All these parameters tend to be significantly better in the group of transplanted patients in comparisons with a historical cohort of age-and sex-matched patients with rp-dcSSc presenting with similar clinical features, treated either with immunosuppressive regimens based on pulse CYC or with less aggressive and conservative therapeutic measures. The mRss score appears to have a slow trend to reduction also in the control group. This is an expected figure since it has been observed that there is a slowly progressive decrease in this parameter related to evolving skin fibrotic changes during the long-term disease course, 19 and not due to treatment as rapidly happens in transplanted patients.
This open study confirms the results obtained in a number of previously published case reports and series of patients with dcSSc where the efficacy of AHSCT treatment in SSc was tested (reviewed in Naraghi et al. 11 ), and also in more recently published multicenter controlled trials 12, 13 where the outcome of transplantation procedure in patients with SSc was compared with that of well-defined CYC treatment regimens.
A recent multicenter retrospective study has demonstrated that the use of selected CD34+ cells for AHSCT in patients with SSc did not add any benefit to the outcome with respect to the use of nonselected cells. 20 This finding should certainly be considered for future research protocols. We adopted the strategy of CD34+ selection for AHSCT at the beginning of our survey, following some literature data which, at that time, indicated a potential beneficial effect of this procedure in autoimmune diseases, probably due to the preliminary elimination of auto-reactive cells. 20 In the present study, we observed an early drastic reduction of skin thickening in the AHSCT-treated group. Such a result is most important, since persistently high mRss values have been shown to be a predictor of poor disease outcome and high mortality rate. 21, 22 Notably, the present study is the first that included a validated scoring system to assess disease activity among the Table 2 . Mean (and 95% CI) ESSG score, mRss and DLCO values in AHSCT-treated patients at the baseline time before transplantation (T0) and after 2 years (T2) and 5 years (T5) of follow-up Group A Group B   T0  T2  T5  T0  T2  T5 ESSG score Mean (CI) 6.7 (6.0-7.3) 2.1 (1.4-2.7) 2.0 (0. outcome measures adopted to evaluate the treatment efficacy. We believe this is a very important issue, since patients presenting a rapidly evolving and active disease could be the best candidates to undergo such an extremely aggressive treatment, and to have the best possible results. Finally, the present study demonstrates that the patients selected in the control groups with comparable levels of disease activity had a 5-year probability of survival of around 40%. This figure certainly makes the AHSCT-related mortality risk more acceptable. AHSCT-related mortality is reasonably low in our series and at least comparable to that reported in ASTIS trials. 13 Recent studies suggest that a relevant lowering of mortality, as a direct consequence of AHSCT, could be achieved thanks to a more accurate selection of candidate patients and, namely, to a more careful pre-transplant evaluation of lung and heart conditions. 23 This more careful patient selection was suggested after the retrospective analysis of the AHSCT-treated patients that demonstrated that most of the patients that died after AHSCT had such a bad outcome because of poor cardiac conditions before transplant. 23 Thus, a more accurate heart assessment before directing a patient to AHSCT is certainly needed. Right catheterization with fluid challenge and heart magnetic resonance evaluation are the diagnostic tools that have been proposed for this purpose. 24 We did perform fluid challenge only in some of the candidate patients, while the others underwent an accurate echocardiographic evaluation. Furthermore, we excluded from the transplantation procedure also patients with fairly severe lung involvement, that is, with a DLCO below 50% of predicted value. This may account for our quite low transplantation-related mortality rate.
We are aware that our study suffers from some methodological limitations. First of all, this is a single-center open study, so the results herein described cannot have the same scientific power of those derived from a multicenter controlled trial. Second, the control group we adopted was a historical one, that is, a cohort of patients selected on the basis of demographic and clinical characteristics similar to those of the transplanted patients, but retrospectively analyzed. This may introduce a bias, when one considers the recent paper by Ferri et al., 3 demonstrating that the 10-year survival observed in cohorts of patients with SSc collected in more recent decades was improved with respect to what was reported in cohorts of older patients. This could be ascribed to the availability of more precise and effective diagnostic tools that allow to define the diagnosis in earlier stages, and to the improvement of therapeutic measures. However, the most significantly lower survival difference was observed in cohorts described before 1970s. 3 This is not the case in the present study since the patients included in the control group were referred to our rheumatology unit after 1990. The demonstration that there is no difference in the survival rate between patients selected before 2004 and during and after this year seems to support this statement.
Our study confirms that different and more aggressive therapeutic strategies may certainly prolong the life of patient suffering from the more severe variants of SSc. From this point of view, AHSCT works much better than immunosuppressive therapy alone.
Although the present study is a single-center open study, the number of transplanted patients with rp-dcSSc enrolled for AHSCT is among the largest ones reported in similarly designed studies. 24 It is also comparable to the number of transplanted patients enrolled in one of the controlled trials so far completed. 12 This trial was stopped early when only 19 patients were recruited in the AHSCT arm because of the evident superiority of this therapeutic procedure with respect to monthly pulse CYC regimen. In this trial, the inclusion and exclusion criteria and the outcome measures that were adopted appear to be very similar to those chosen in our study design. So, the superiority of the AHSCT procedure with respect to immunosuppressive therapies is so strong that it can be statistically evident even in numerically limited series of patients.
In conclusion, our study confirms that AHSCT is a good therapeutic option for the treatment of patients with rp-dcSSc. Although this procedure maintains a certain risk of mortality, it induces, in the great majority of treated patients, a drastic improvement in survival, a dramatic reduction of disease activity and skin thickening, and, finally, a stabilization of lung function. Our study also suggests that patients with a high level of disease activity, severe skin involvement and without severe heart and lung involvement before transplantation procedure could be the best candidates to undergo this aggressive treatment.
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